Nano-X Imaging Ltd.
All Connections
3 total
All Connections
3 totalRan Poliakine was co-named in the SEC enforcement action alongside Nano-X Imaging Ltd. and settled separately in October 2023. As founder and Chairman he exercised effective control over the corporate disclosures that were found to be misleading regarding the development cost of the Nanox.ARC prototype.
American Capital Partners, LLC acted as sole placement agent for the November 2025 registered direct offering of 3,826,530 NNOX shares at $3.92 per share to a single unnamed institutional investor. Net proceeds to Nano-X: ~$14.2M.
Cantor Fitzgerald & Co. and Mizuho Securities USA LLC were named as agents in the June 2024 ATM (controlled equity offering) sales agreement for up to $100M in ordinary shares at a 3% commission rate. This facility was in place from May 2024 until at least November 2025.
All Findings
8 total
All Findings
8 totalfinancial (4)
Prior ATM facility (Cantor Fitzgerald/Mizuho, up to $100M at $8.10) established June 2024 has been replaced by new F-3 shelf in March 2026 as stock declined 73%
424B5 filed June 7, 2024 establishing ATM facility with Cantor Fitzgerald & Co. and Mizuho Securities USA LLC for up to $100M. Stock at $8.10 per share. 3% maximum commission. The November 2025 registered direct used the same shelf registration (File No. 333-271688). The new March 2026 F-3 appears to replace or supplement this facility now that stock has declined 73% from $8.10.
FY2024 financials: revenue $11.3M vs COGS $21.9M (gross margin -94%), net loss $53.5M, accumulated deficit $378.7M, ~$73M liquid assets, $36M annual cash burn
FY2024 revenue: $11.3M; cost of revenue: $21.9M; gross loss: $(10.6M); gross margin: -94%. Net loss: $(53.5M). Operating cash burn: $(36.4M). Accumulated deficit: $378.7M. Cash: $39.3M + $15.5M short-term deposits + $18.4M marketable securities = $73.2M liquid. Working capital: $64.7M. Company describes itself as 'initial launch-stage company' expecting continued losses.
Nov 2025 registered direct offering: 3.83M shares at $3.92 to single unnamed institutional investor via American Capital Partners; that investor now ~44% underwater at current $2.21
424B5 prospectus supplement for registered direct offering of 3,826,530 shares at $3.92 per share to a single unnamed institutional investor. Gross proceeds ~$15.0M, net ~$14.2M. Placement agent: American Capital Partners, LLC. As of Sept 30, 2025 shares outstanding: 65,382,892. One outstanding warrant for 2,142,858 shares currently exercisable.
Nano-X filed new $100M F-3 shelf at historically depressed stock price ($2.21-$2.58), representing potential dilution of ~65% of current market cap ($154M)
New F-3 shelf registration filed 2026-03-13 for up to $100,000,000 in ordinary shares, warrants, and debt securities. Amended via F-3/A on 2026-03-26. Stock price on reference date (March 12, 2026): $2.58. Current price March 27, 2026: $2.21. At $2.21, $100M shelf implies issuance of ~45.2M additional shares against ~69M outstanding = ~65% dilution.
legal (1)
Nano-X Imaging settled two securities class action lawsuits for $8 million; allegations of securities law violations against former officers and a director
Two securities class action complaints asserting violations of federal securities laws. Settlement agreement entered June 2, 2023 for $8 million, approved by court May 7, 2024. Defendants included former officers and a director.
regulatory (1)
Nano-X Imaging settled SEC enforcement action for false cost disclosures; $650K penalty, permanent injunction; founder/Chairman Ran Poliakine paid additional penalties
The Company paid a civil penalty in the amount of $650,000 and is permanently enjoined from violating Section 17(a)(2) of the Securities Act and Section 13(a) of the Securities Exchange and Rules 12b-20 and 13a-1 thereunder. Former Chairman Ran Poliakine paid disgorgement of $240,000, prejudgment interest of $26,836.39, a civil penalty of $150,000, and was permanently enjoined. Investigation related to development cost of Nanox.ARC prototypes and cost estimates for assembling at scale.
governance (2)
Founder and Chairman Ran Poliakine died January 2024 following SEC enforcement settlement; Israeli litigation against his estate and Nanox Gibraltar entity is ongoing
Ran Poliakine, founder and former Chairman of the Board, died in January 2024. He had faced SEC enforcement action and paid $240K disgorgement + $26,836 interest + $150K civil penalty. A claim is also pending in Israel against Nanox Gibraltar and Poliakine's estate alleging breach of consulting agreement.
HFIA wave: 9 insiders newly visible via Form 3 filings March 2026; Erez Meltzer holds at-the-money options at $2.21; Noga Kainan holds shares through I.B.L. Business Consulting Ltd vehicle
Eight initial Form 3 statements filed by Nano-X insiders on March 18-24, 2026 under HFIA Section 16 compliance. Insiders include Erez Meltzer (Director & Officer, 60,584 shares + options at $2.21/ATM, $23.84, $11.52), James Dara (Officer, 39,474 RSUs + options at $49.68, $17.63×2, $11.52), Feler Marina Gofman (Officer, 20,000 direct + 26,316 RSUs), Ofir Koren (Officer), Cohen Tamar Aharon (Officer), Michael Jackman (role not disclosed), Noga Kainan (794 shares via I.B.L. Business Consulting Ltd vehicle), Nehama Ronen (7,792 shares + 17,544 RSUs). Only CFO Ran Daniel had prior Section 16 reporting (Sept 2025).